Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery ...
A new study led by Winship Cancer Institute of Emory University and Abramson Cancer Center of University of Pennsylvania researchers demonstrates that a first-of-its-kind platform using artificial ...
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...
Eric Joseph, an analyst from J.P. Morgan, maintained the Hold rating on Vir Biotechnology (VIR – Research Report). The associated price target ...
Trial underscores IROS's commitment to developing innovative therapies for unmet medical needs <li /> The study's success ...
An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...
The gene neuropilin2 encodes a receptor involved in cell-cell interactions in the brain and plays a key role in regulating ...
An estimated 610,000 people in the US died from cancer last year. That’s almost the same amount of people who perished in the country’s four-year civil war. At least two million more people were ...
Imagine having a digital carbon copy of yourself that physicians could use to predict long-term risks for disease, assess how your body may respond to treatment, and simulate surgeries in advance. A ...
The global artificial intelligence in clinical trials market, valued at US$1.20 billion in 2023, is forecasted to grow at a ...
US-based Halia Therapeutics’ new therapy will be put to a six-month-long trial that will involve 60 patients with type 2 ...
A multidisciplinary team of University of Miami researchers studying factors associated with health outcomes and disease risk in the Hispanic community has received a $21 million grant from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback